Results 51 to 60 of about 12,537,270 (248)

Association between non-high-density lipoprotein cholesterol and high-risk intraductal papillary mucinous neoplasm

Discover Oncology
Background Serum cholesterol level plays a vital role in cancer development. Several studies have suggested a potential relationship between non-high-density lipoprotein cholesterol (non-HDL-c) levels and cancer risk.
Yongkang Liu, Weixiao Zhang, Chuangen Guo, Jianhua Wang, Xiao Chen   +4 more
doaj   +1 more source

Association of non-high-density lipoprotein cholesterol trajectories with the development of non-alcoholic fatty liver disease: an epidemiological and genome-wide association study

Journal of Translational Medicine, 2023
Background Non-alcoholic fatty liver disease (NAFLD) shares common risk factors with cardiovascular diseases. Effects of longitudinal trends in non-high-density lipoprotein (non-HDL) cholesterol on NAFLD development are not understood.
Jun-Hyuk Lee, Jiyeon Kim, Jung Oh Kim, Yu-Jin Kwon   +3 more
doaj   +1 more source

Protein and cell therapy for lecithin-cholesterol acyltransferase (LCAT) deficiency [PDF]

, 2009
Lecithin-cholesterol acyltransferase (LCAT) is an enzyme principally secreted by the liver into the circulation where it esterifies cholesterol and plays a key role in high- density lipoprotein (HDL) metabolism. In familial and acquired (liver disease)
Low, J K, Low, J.K.
core  

Polystyrene Nanoplastics Drive β‐Cell Dedifferentiation Through Dendritic Cell‐Intrinsic MHC‐I‐Dependent Inflammatory Crosstalk

Advanced Science, EarlyView.
Polystyrene nanoplastics disrupt pancreatic immune–endocrine homeostasis by promoting MHC‐I‐associated dendritic cell activation and inflammatory crosstalk with β cells. This immune remodeling drives β‐cell dedifferentiation, impairs insulin secretion, and aggravates metabolic dysfunction, revealing a previously unrecognized immunometabolic mechanism ...
Conghui Qiao, Yuqing Song, Fang Yang, Menghui Guo, Libin Jiang, Xiaoyue Quan, Wei Wei, Xinyang Wang, Tianshu Han, Mingyuan Liu, Wenbo Jiang   +10 more
wiley   +1 more source

Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion

Hepatology, EarlyView., 2022
The role of SMLR1 in lipid metabolism (high fat + cholesterol diet in mice) Abstract Background and Aims The assembly and secretion of VLDL from the liver, a pathway that affects hepatic and plasma lipids, remains incompletely understood. We set out to identify players in the VLDL biogenesis pathway by identifying genes that are co‐expressed with the ...
Willemien van Zwol, Antoine Rimbert, Justina C. Wolters, Marieke Smit, Vincent W. Bloks, Niels J. Kloosterhuis, Nicolette C. A. Huijkman, Mirjam H. Koster, Umesh Tharehalli, Simon M. de Neck, Colin Bournez, Marceline M. Fuh, Jeroen Kuipers, Sujith Rajan, Alain de Bruin, Henry N. Ginsberg, Gerard J. P. van Westen, M. Mahmood Hussain, Ludger Scheja, Joerg Heeren, Philip Zimmerman, Bart van de Sluis, Jan Albert Kuivenhoven   +22 more
wiley   +1 more source

Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background

Journal of Lipid Research
The selective cholesteryl ester transfer protein (CETP) inhibitor obicetrapib is in clinical evaluation for dyslipidemia and cardiovascular risk reduction.
José A. Inia, Leo H. Zhang, Nanda Keijzer, Nicole Worms, Anita van Nieuwkoop-van Straalen, Marc Ditmarsch, Mathijs de Kleer, J. Wouter Jukema, John J.P. Kastelein, Michael Szarek, Anita M. van den Hoek, Geurt Stokman, Elsbet J. Pieterman, Hans M.G. Princen   +13 more
doaj   +1 more source

The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China. [PDF]

PLoS ONE, 2015
Dyslipidemia is a major health problem in China and an important modifiable cardiovascular disease (CVD) risk factor. This study aimed to describe the prevalence of dyslipidemia and low high density lipoprotein cholesterol (HDL-cholesterol) and ...
Pengfei Ge, Caixia Dong, Xiaolan Ren, Elisabete Weiderpass, Chouji Zhang, Haoqiang Fan, Jing Zhang, Yongrui Zhang, Jinen Xi   +8 more
doaj   +1 more source

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

Advanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan, Yijie Qiu, Yan Zhu, Quan Wang, Jiangtao Lin, Yourong Duan, Qi Wang, Yi Dong   +7 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Management of triglycerides, non-high density lipoprotein cholesterol and high density lipoprotein cholesterol

Indian Heart Journal
Dyslipidaemia characterised by elevated total cholesterol/LDL-C, triglyceride or both or decreased HDL-C is an important risk factor for the development of ASCVD. Atherogenic dyslipidaemia characterised by high TG, low HDL-C and elevated small dense LDL (
Geevar Zachariah
doaj   +1 more source